Camlin Fine Sciences · NSE: CAMLINFINE · BSE: 532834
Q4 FY25 results · Jan–Mar 2025
Camlin Fine Sciences reported revenue from operations of ₹437.46 crore (up 8.9% from Q4 FY24) and net profit of ₹0.11 crore for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 437.46 | 401.69 | +8.9% | 433.49 | +0.9% |
| Other income | 9.59 | 5.76 | +66.4% | 1.34 | +617.9% |
| Total income | 447.06 | 407.46 | +9.7% | 434.83 | +2.8% |
| Profit before share of associates & JVs and tax | 28.91 | (93.51) | Turned profit | 1.52 | 19x |
| Share of profit/(loss) of associates & JVs | 1.79 | 0.00 | (1.85) | ||
| Net profit for the period | 0.11 | (81.79) | Turned profit | (7.47) | Turned profit |
| Attributable to shareholders of the company | (0.72) | (77.14) | Loss narrowed | (4.14) | Loss narrowed |
| EPS, basic (₹) | (0.04) | (4.64) | not comparable | (0.24) | not comparable |
| Net margin (%) | 0.0 | -20.4 | -1.7 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 272.60 | 220.33 | +23.7% | 205.07 | +32.9% |
| Other income | 8.94 | 5.55 | +61.0% | 6.82 | +31.1% |
| Total income | 281.53 | 225.88 | +24.6% | 211.89 | +32.9% |
| Profit before tax | 11.90 | (48.68) | Turned profit | (7.19) | Turned profit |
| Net profit for the period | 15.62 | (44.07) | Turned profit | (5.63) | Turned profit |
| EPS, basic (₹) | 0.86 | (2.65) | not comparable | (0.33) | not comparable |
| Net margin (%) | 5.7 | -20.0 | -2.7 |
Consolidated
- Filed with BSE
- 09 Jul 2025, 16:14 IST
- Board meeting
- 23 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Jul 2025, 16:14 IST
- Board meeting
- 23 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE